Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technolo...(--------- --------- --------- -----...)

Date:11/6/2009

--------- --------- --------- -------- Mean FPG at baseline (mg/dL) 161.2 170.5 171.8 145.1 --------------------------- ----- ----- ----- ----- Mean FPG at end of treatment (mg/dL) 155.6 139.4 129.8 116.3 ---------------------------- ----- ----- ----- ----- Change from baseline (mg/dL) -5.6 -31.1* -42.0* -28.8* --------------------------- ---- -------- -------- ------- Change in 2-hr PPG at end of treatment (mg/dL) -16.3 -34.7* -47.1* -69.6* ------------------------- ----- -------- -------- ------- *p = < 0.05

Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours after initiation of treatment, suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions. Changes from baseline in FPG and PPG were statistically significant for the 20 mcg/day, 40 mcg/day and 80 mcg/day doses.

    HbA1c & Body Weight           ITCA 650 Dose Arms (continuous daily dose)
                                  -----------------------------------------
                                     10          20          40        80
                                   mcg/day     mcg/day     mcg/day   mcg/day
                                 ---------   ---------   --------- --------
    % HbA1c at baseline              7.67        7.90        7.45     7.38
    -------------------              ----        ----        ----     ----
    % HbA1c at end of treatment      7.15        7.28        7.00     6.80
    ---------------------------      ----        ----        ----     ----
    Change from baseline            -0.54*      -0.62*      -0.45*   -0.73*
    ----
'/>"/>
SOURCE  Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger